AKIGAI is a biotech-startup whose founders hold global use patents for a drug class that has been given to millions of people for over 20 years. Because we have witnessed the effects again and again. Like many breakthrough discoveries in medicine, the understanding that relief of neuropathic pain was a result of EGFR inhibition came serendipitously.